Suchergebnisse - "COVID-19 treatment"

PubPharm (330)

51

A Study to Learn About the Study Medicines Called Nirmatrelvir/Ritonavir in People at Least 12 Years of Age With COVID-19 Who Are Immunocompromised : AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED

enthalten in: WHO International Clinical Trials Registry Platform | 2023

52

A Study to Learn About the Study Medicines Called Nirmatrelvir/Ritonavir in People at Least 12 Years of Age With COVID-19 Who Are Immunocompromised : AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED

enthalten in: WHO International Clinical Trials Registry Platform | 2023

53

Short Title: Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)INSIGHT 012 : An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19 - Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)

enthalten in: WHO International Clinical Trials Registry Platform | 2023

54

A Study to Learn About a Repeat 5-Day Treatment with Nirmatrelvir/Ritonavir in People with Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment with Nirmatrelvir/Ritonavir : AN INTERVENTIONAL, EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE A REPEAT 5-DAY COURSE OF NIRMATRELVIR/RITONAVIR COMPARED TO PLACEBO/RITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID-19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY

enthalten in: WHO International Clinical Trials Registry Platform | 2023

55

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19 : AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, DOUBLE BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR COMPARED WITH PLACEBO/RITONAVIR FOR THE TREATMENT OF SEVERE COVID-19 IN HOSPITALIZED PARTICIPANTS WHO ARE IMMUNOCOMPROMISED OR AT INCREASED RISK FOR SEVERE COVID-19 OUTCOMES

enthalten in: WHO International Clinical Trials Registry Platform | 2023

56

Evaluation of the efficacy and safety of a polyclonal equine fragments immunotherapy (FBR-002) in participants with COVID-19 requiring supplemental oxygen in hospital and at risk of severe outcome : A phase IIb randomized, placebo-controlled, double-blind study, to evaluate the efficacy and safety of FBR-002 in participants hospitalized with COVID-19 in need of supplemental oxygen and at risk of severe outcome

enthalten in: WHO International Clinical Trials Registry Platform | 2023

57

A Study to Learn About the Study Medicines Called Nirmatrelvir/Ritonavir in People at Least 12 Years of Age With COVID-19 Who Are Immunocompromised : AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED

enthalten in: WHO International Clinical Trials Registry Platform | 2023

58

A Study to Learn About the Study Medicines Called Nirmatrelvir/Ritonavir in People at Least 12 Years of Age With COVID-19 Who Are Immunocompromised : AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED

enthalten in: WHO International Clinical Trials Registry Platform | 2023

59

Efficacy of therapeutic plasma exchange in severe COVID-19 disease : A meta-analysis

enthalten in: Vox sanguinis | 2023

von Prakash, S. | Sahu, A. | Routray, S. | +3

60

Paxlovid-Induced Symptomatic Bradycardia and Syncope

enthalten in: Cureus | 2023

von Ganipisetti, V. | Bollimunta, P. | Maringanti, S.